Corporate News

Medios AG continues its dynamic growth in the 1st quarter and confirms its sales revenue forecast for fiscal year 2017

- Sales revenue in the 1st quarter of 2017 reach EUR 51.8 million and thereby already more than a quarter of expected annual sales revenue

- The high demand for personalized medicine continues

Berlin, 17 May 2017 - Medios AG, a competence partner and solution provider in the Speciality Pharma segment, has continued its dynamic growth in the 1st quarter of 2017 and confirms its sales revenue forecast for fiscal year 2017. In the period from January to March, the company already generated sales revenue of EUR 51.8 million (IFRS), more than a quarter of the around EUR 200 million sales revenue expected for the entire year. The forecast for earnings before taxes (EBT) of around EUR 7 million also remains unchanged.

Manfred Schneider, CEO of Medios AG: "Thanks to the sustained high demand for personalized medicine, we have started the new fiscal year off very positively and are well on our way to reaching our 2017 sales revenue goal of around 200 million euro. In the first three months, we have laid the groundwork for long-term growth by forming our new subsidiary, Medios Digital, and by investing in the significant expansion of our manufacturing capacities."

In January, Medios AG announced the foundation of a wholly owned subsidiary, Medios Digital GmbH. The goal of the company's in-house system service provider is to bundle the software development activities performed by the Medios Group and to drive the digitalization of the pharma trade with specialty drugs forward.

In March, Medios AG purchased a property in Berlin-Charlottenburg to significantly expand production for its subsidiary, Medios Manufaktur GmbH, and to merge all activities of the Medios Group on one site. The total investment in this property amounts to around EUR 11 million.

In the same month, the new law on strengthening pharmaceutical supply in statutory health insurance was passed by the German parliament and the German Bundestag and Bundesrat. It has taken effect in May and, according to the management board, could not only improve healthcare for patients but could also have a positive impact on the growth opportunities of Medios AG.

In April, Medios AG published its first annual report. According to this report, the company was able to continue its dynamic growth in 2016 thanks to extremely positive development in the Specialty Pharma market. Based on the pro forma profit and loss statement (IFRS), the corporation's sales revenue rose by 78 percent to EUR 160.4 million compared to the prior year. Earnings before taxes (EBT) likewise increased significantly by 106.1 percent to EUR 5.77 million.

About Medios AG
Medios AG positions itself - along with its sister companies Medios Pharma, Medios Manufaktur and Medios Digital - as a competence partner and solution provider for the Specialty Pharma segment. Medios AG interconnects individual actors within the market and turns them into co-operating partners. It is our goal to guarantee best possible pharmaceutical care for patients while providing our partners and clients with integrated solutions along the supply chain. Specialty Pharma medicine are pharmaceuticals for patients with rare and chronic diseases such as certain cancer types and autoimmune / infectious diseases, which are time-consuming and cost-intensive to cure.

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Herrengraben 1
20459 Hamburg
Telefon: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.